Bradley Foster & Sargent Inc. CT Sells 100,560 Shares of Boston Scientific Corporation $BSX

Bradley Foster & Sargent Inc. CT reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 18.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 453,864 shares of the medical equipment provider’s stock after selling 100,560 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Boston Scientific were worth $44,311,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Boston Scientific during the 2nd quarter worth $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific during the second quarter worth about $746,655,000. Parnassus Investments LLC lifted its holdings in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 1.2%

Shares of BSX opened at $75.27 on Wednesday. The stock’s 50-day moving average price is $88.52 and its two-hundred day moving average price is $96.13. Boston Scientific Corporation has a 12 month low of $72.69 and a 12 month high of $109.50. The company has a market capitalization of $111.70 billion, a PE ratio of 38.80, a PEG ratio of 1.03 and a beta of 0.67. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the company earned $0.70 earnings per share. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on BSX shares. Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Truist Financial dropped their price target on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Royal Bank Of Canada lowered their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, Barclays dropped their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.